Byron H. Long

3.1k total citations
57 papers, 2.5k citations indexed

About

Byron H. Long is a scholar working on Oncology, Molecular Biology and Organic Chemistry. According to data from OpenAlex, Byron H. Long has authored 57 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 31 papers in Molecular Biology and 21 papers in Organic Chemistry. Recurrent topics in Byron H. Long's work include Cancer Treatment and Pharmacology (34 papers), Cancer therapeutics and mechanisms (21 papers) and Synthetic Organic Chemistry Methods (17 papers). Byron H. Long is often cited by papers focused on Cancer Treatment and Pharmacology (34 papers), Cancer therapeutics and mechanisms (21 papers) and Synthetic Organic Chemistry Methods (17 papers). Byron H. Long collaborates with scholars based in United States, Germany and Belgium. Byron H. Long's co-authors include Michael G. Brattain, Craig R. Fairchild, William C. Rose, Francis Y. F. Lee, Soong‐Hoon Kim, Gregory D. Vite, A.O. Pogo, R. M. Borzilleri, Dolatrai M. Vyas and Robert A. Kramer and has published in prestigious journals such as Cell, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

Byron H. Long

57 papers receiving 2.4k citations

Peers

Byron H. Long

ONCOL

PHARM

Sergio Penco Italy

Anna Maria Casazza Italy

Akira Asai Japan

Gregory D. Vite United States

Ruoli Bai United States

Andrzej Składanowski Poland

Frank Totzke Germany

Sanjeev Shangary United States

Swee Y. Sharp United Kingdom

Carolyn Discafani United States

Sergio Penco Italy

Byron H. Long

1.9k ×1.4

830 ×0.7

ONCOL

1.1k ×1.3

485 ×1.2

295 ×0.8

PHARM

Citations per year, relative to Byron H. Long Byron H. Long (= 1×) peers Sergio Penco

Countries citing papers authored by Byron H. Long

Since Specialization

Citations

This map shows the geographic impact of Byron H. Long's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Byron H. Long with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Byron H. Long more than expected).

Fields of papers citing papers by Byron H. Long

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Byron H. Long. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Byron H. Long. The network helps show where Byron H. Long may publish in the future.

Co-authorship network of co-authors of Byron H. Long

This figure shows the co-authorship network connecting the top 25 collaborators of Byron H. Long. A scholar is included among the top collaborators of Byron H. Long based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Byron H. Long. Byron H. Long is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rose, William C., Punit H. Marathe, Graham Jang, et al.. (2005). Novel fluoro-substituted camptothecins: in vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization. Cancer Chemotherapy and Pharmacology. 58(1). 73–85. 12 indexed citations

Mastalerz, Harold, Craig R. Fairchild, Steven Hansel, et al.. (2003). The discovery of BMS-275183: an orally efficacious novel taxane. Bioorganic & Medicinal Chemistry. 11(20). 4315–4323. 39 indexed citations

Long, Byron H., William Rose, Dolatrai M. Vyas, James A. Matson, & Salvatore Forenza. (2002). Discovery of Antitumor Indolocarbazoles: Rebeccamycin, NSC 655649, and Fluoroindolocarbazoles. PubMed. 2(2). 255–266. 68 indexed citations

Chordia, Mahendra D., Haiqing Yuan, Prakash G. Jagtap, et al.. (2001). Synthesis and bioactivity of 2,4-diacyl analogues of paclitaxel. Bioorganic & Medicinal Chemistry. 9(1). 171–178. 12 indexed citations

Wittman, Mark D., John F. Kadow, Dolatrai M. Vyas, et al.. (2001). Synthesis and antitumor activity of novel paclitaxel–chlorambucil hybrids. Bioorganic & Medicinal Chemistry Letters. 11(6). 811–814. 18 indexed citations

Wittman, Mark D., Craig R. Fairchild, Kathy Johnston, et al.. (2001). Synthesis of metabolically blocked paclitaxel analogues. Bioorganic & Medicinal Chemistry Letters. 11(6). 809–810. 7 indexed citations

Kingston, David G. I., Mahendra D. Chordia, Prakash G. Jagtap, et al.. (1999). Synthesis and Biological Evaluation of 1-Deoxypaclitaxel Analogues. The Journal of Organic Chemistry. 64(6). 1814–1822. 29 indexed citations

Yuan, Haiqing, David G. I. Kingston, Byron H. Long, Craig Fairchild, & Kathy Johnston. (1999). Synthesis and biological evaluation of C-1 and ring modified A-norpaclitaxels. Tetrahedron. 55(30). 9089–9100. 4 indexed citations

Kingston, David G. I., Ashok Chaudhary, Mahendra D. Chordia, et al.. (1998). Synthesis and Biological Evaluation of 2-Acyl Analogues of Paclitaxel (Taxol). Journal of Medicinal Chemistry. 41(19). 3715–3726. 54 indexed citations

10.

Kerns, Edward H., Susan E. Hill, Kevin J. Volk, et al.. (1998). Cellular uptake profile of paclitaxel using liquid chromatography tandem mass spectrometry. Rapid Communications in Mass Spectrometry. 12(10). 620–624. 17 indexed citations

11.

Chordia, Mahendra D., David G. I. Kingston, Ernest Hamel, et al.. (1997). Synthesis and biological activity of A-nor-paclitaxel analogues. Bioorganic & Medicinal Chemistry. 5(5). 941–947. 12 indexed citations

12.

Fairchild, Craig, et al.. (1995). Synthesis and Biological Evaluation of Novel C-4 Aziridine-Bearing Paclitaxel (Taxol) Analogs. Journal of Medicinal Chemistry. 38(12). 2263–2267. 10 indexed citations

13.

Long, Byron H., et al.. (1994). Structure-activity relationships of VP-16 analogues. Cancer Chemotherapy and Pharmacology. 34(S1). S26–S31. 18 indexed citations

14.

Krishnan, Bala, et al.. (1994). Fluorescence Polarization Studies of the Binding of BMS 181176 to DNA. Journal of Biomolecular Structure and Dynamics. 12(3). 625–636. 12 indexed citations

15.

Lorico, Aurelio & Byron H. Long. (1993). Biochemical characterisation of elsamicin and other coumarin-related antitumour agents as potent inhibitors of human topoisomerase II. European Journal of Cancer. 29(14). 1985–1991. 48 indexed citations

16.

Saulnier, Mark G., et al.. (1992). Synthesis of biological evaluation of 4′-deshydroxy-4′-methyl etoposide and teniposide analogs. Bioorganic & Medicinal Chemistry Letters. 2(10). 1213–1218. 5 indexed citations

17.

Saulnier, Mark G., Dolatrai M. Vyas, David R. Langley, et al.. (1989). E-ring desoxy analogs of etoposide. Journal of Medicinal Chemistry. 32(7). 1418–1420. 26 indexed citations

18.

Long, Byron H. & Dale A. Stringfellow. (1988). Inhibitors of topoisomerase II: Structure-activity relationships and mechanism of action of podophyllin congeners. Advances in Enzyme Regulation. 27. 211–214. 41 indexed citations

19.

Long, Byron H., et al.. (1987). DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide. Lung Cancer. 3(1). 20–20. 66 indexed citations

20.

Willson, James K. V., Byron H. Long, Michael Marks, et al.. (1984). Mitomycin C resistance in a human colon carcinoma cell line associated with cell surface protein alterations.. PubMed. 44(12 Pt 1). 5880–5. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact